Molecular decoys: antidotes, therapeutics and immunomodulators

Current Opinion in Biotechnology

Volumn 19, Issue 6, 2008, Pages 644-651

  Gershoni, Jonathan M ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; CELL DEATH; CELL PROLIFERATION; CYTOLOGY; LIGANDS; METABOLITES; PHYSIOLOGY;

APOPTOSIS; CELL PHYSIOLOGIES; CELLULAR REGULATIONS; FINE TUNES; IMMUNOMODULATORS; INFECTIOUS AGENTS; INFLAMMATORY DISEASES; LIGAND INTERACTIONS; SOLUBLE RECEPTORS;

SIGNAL TRANSDUCTION;

ADALIMUMAB; AFLIBERCEPT; ANTIDOTE; ANTITOXIN; ANTIVIRUS AGENT; BEVACIZUMAB; CAPILLARY MORPHOGENESIS PROTEIN 2; CD4 ANTIBODY; DECOY RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR; ETANERCEPT; GAMMA INTERFERON RECEPTOR; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6 RECEPTOR; MEMBRANE PROTEIN; NICOTINIC RECEPTOR; PROBIOTIC AGENT; TELOVAMER; TOXIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; UNCLASSIFIED DRUG;

APOPTOSIS; CELL FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; CROHN DISEASE; DRUG BINDING; ESCHERICHIA COLI; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFECTION PREVENTION; INFLAMMATION; LUNG NON SMALL CELL CANCER; MOLECULAR DYNAMICS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS;

ANIMALS; ANTIDOTES; IMMUNOLOGIC FACTORS; MOLECULAR MIMICRY;

EID: 57049110955     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2008.10.001     Document Type: Review

References (79)

1. Ehrlich P: On immunity with special reference to cell life. The Croonian Lecture 1900 pp 428-448.
2. Prull C.R. Part of a scientific master plan? Paul Ehrlich and the origins of his receptor concept. Med Hist 47 (2003) 332-356
3. Langley JN: On nerve endings and on special excitable substances in cells. The Croonian Lecture 1906 pp 170-194.
4. Maehle A.-H. 'Receptive substances': John Newport Langley (1852-1925) and his path to receptor theory of drug action. Med Hist 48 (2004) 153-174
5. Sharon N. Carbohydrates as future anti-adhesion drugs for infectious diseases. Biochim Biophys Acta 1760 (2006) 527-537. A comprehensive review of the role of carbohydrate 'receptors' and bacterial lectin-like molecules that mediate adhesion. The structures of the glycomoeities and their recognition are described as well as a discussion of the potential applications for anti-adhesion therapy.
6. Svanborg Eden C., Hagberg L., Leffler H., and Lomberg H. Recent progress in the understanding of the role of bacterial adhesion in the pathogenesis of urinary tract infection. Infection 10 (1982) 327-332
7. Castagliuolo I., LaMont J.T., Qiu B., Nikulasson S.T., and Pothoulakis C. A receptor decoy inhibits the enterotoxic effects of Clostridium difficile toxin A in rat ileum. Gastroenterology 111 (1996) 433-438
8. Paton A.W., Morona R., and Paton J.C. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat Med 6 (2000) 265-270
9. Sullenger B.A., Gallardo H.F., Ungers G.E., and Gilboa E. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 63 (1990) 601-608
10. Mann M.J., and Dzau V.J. Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest 106 (2000) 1071-1075
11. Tomita N., Morishita R., Tomita T., and Ogihara T. Potential therapeutic applications of decoy oligonucleotides. Curr Opin Mol Ther 4 (2002) 166-170
12. Moriyama I., Ishihara S., Rumi M.A., Aziz M.D., Mishima Y., Oshima N., Kadota C., Kadowaki Y., Amano Y., and Kinoshita Y. Decoy oligodeoxynucleotide targeting activator protein-1 (AP-1) attenuates intestinal inflammation in murine experimental colitis. Lab Invest 88 (2008) 652-663. A comparative analysis of AP-1 vs NFkB decoys and their application in suppressing intestinal inflammation in a mouse model.
13. Azuma H., Tomita N., Sakamoto T., Kiyama S., Inamoto T., Takahara K., Kotake Y., Segawa N., Morishita R., Takahara S., et al. Marked regression of liver metastasis by combined therapy of ultrasound-mediated NF kappaB-decoy transfer and transportal injection of paclitaxel, in mouse. Int J Cancer 122 (2008) 1645-1656. A major problem in the application of oligonucleotide decoys is the method of delivery. Here the application of ultrasound is described as a means to deliver NFkB decoys in the treatment of liver disease.
14. Changeux J.P., and Taly A. Nicotinic receptors, allosteric proteins and medicine. Trends Mol Med 14 (2008) 93-102
15. Gershoni J.M., Hawrot E., and Lentz T.L. Binding of alpha-bungarotoxin to isolated alpha subunit of the acetylcholine receptor of Torpedo californica: quantitative analysis with protein blots. Proc Natl Acad Sci U S A 80 (1983) 4973-4977
16. Gershoni J.M., and Palade G.E. Protein blotting: principles and applications. Anal Biochem 131 (1983) 1-15
17. Barkas T., Mauron A., Roth B., Alliod C., Tzartos S.J., and Ballivet M. Mapping the main immunogenic region and toxin-binding site of the nicotinic acetylcholine receptor. Science 235 (1987) 77-80
18. Gershoni J.M. Expression of the alpha-bungarotoxin binding site of the nicotinic acetylcholine receptor by Escherichia coli transformants. Proc Natl Acad Sci U S A 84 (1987) 4318-4321
19. Gershoni J.M., and Aronheim A. Molecular decoys: ligand-binding recombinant proteins protect mice from curarimimetic neurotoxins. Proc Natl Acad Sci U S A 85 (1988) 4087-4089
20. Burnett J.C., Henchal E.A., Schmaljohn A.L., and Bavari S. The evolving field of biodefence: therapeutic developments and diagnostics. Nat Rev Drug Discov 4 (2005) 281-297
21. McCormick J.K., Yarwood J.M., and Schlievert P.M. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 55 (2001) 77-104
22. Buonpane R.A., Churchill H.R., Moza B., Sundberg E.J., Peterson M.L., Schlievert P.M., and Kranz D.M. Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists. Nat Med 13 (2007) 725-729. An excellent example of optimization of an anti-toxin decoy. Systematic mutagenesis leads to a marked enhancement of affinity between the Vβ-based decoy and its target. This illustrates the correlation between affinity and decoy efficacy.
23. Bradley K.A., and Young J.A. Anthrax toxin receptor proteins. Biochem Pharmacol 65 (2003) 309-314
24. Scobie H.M., Thomas D., Marlett J.M., Destito G., Wigelsworth D.J., Collier R.J., Young J.A., and Manchester M. A soluble receptor decoy protects rats against anthrax lethal toxin challenge. J Infect Dis 192 (2005) 1047-1051
25. Sweet R.W., Truneh A., and Hendrickson W.A. CD4: its structure, role in immune function and AIDS pathogenesis, and potential as a pharmacological target. Curr Opin Biotechnol 2 (1991) 622-633
26. Capon D.J., Chamow S.M., Mordenti J., Marsters S.A., Gregory T., Mitsuya H., Byrn R.A., Lucas C., Wurm F.M., Groopman J.E., et al. Designing CD4 immunoadhesins for AIDS therapy. Nature 337 (1989) 525-531
27. Ashkenazi A., and Chamow S.M. Immunoadhesins as research tools and therapeutic agents. Curr Opin Immunol 9 (1997) 195-200. Sets the foundations of what has become the standard platform for production of soluble receptors.
28. Daar E.S., Li X.L., Moudgil T., and Ho D.D. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A 87 (1990) 6574-6578
29. Orloff S.L., Kennedy M.S., Belperron A.A., Maddon P.J., and McDougal J.S. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4. J Virol 67 (1993) 1461-1471
30. Moore J.P., and Klasse P.J. Thermodynamic and kinetic analysis of sCD4 binding to HIV-1 virions and of gp120 dissociation. AIDS Res Hum Retroviruses 8 (1992) 443-450
31. Traunecker A., Schneider J., Kiefer H., and Karjalainen K. Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules. Nature 339 (1989) 68-70
32. Van Oijen M.G., and Preijers F.W. Rationale for the use of immunotoxins in the treatment of HIV-infected humans. J Drug Target 5 (1998) 75-91
33. Dey B., Del Castillo C.S., and Berger E.A. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J Virol 77 (2003) 2859-2865
34. Meyuhas R., Noy H., Montefiori D.C., Denisova G., Gershoni J.M., and Gross G. HIV-1 neutralization by chimeric CD4-CG10 polypeptides fused to human IgG1. Mol Immunol 42 (2005) 1099-1109
35. Fletcher C.V., DeVille J.G., Samson P.M., Moye Jr. J.H., Church J.A., Spiegel H.M., Palumbo P., Fenton T., Smith M.E., Graham B., et al. Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children. J Allergy Clin Immunol 119 (2007) 747-750
36. Greve J.M., Forte C.P., Marlor C.W., Meyer A.M., Hoover-Litty H., Wunderlich D., and McClelland A. Mechanisms of receptor-mediated rhinovirus neutralization defined by two soluble forms of ICAM-1. J Virol 65 (1991) 6015-6023
37. Nicodemou A., Petsch M., Konecsni T., Kremser L., Kenndler E., Casasnovas J.M., and Blaas D. Rhinovirus-stabilizing activity of artificial VLDL-receptor variants defines a new mechanism for virus neutralization by soluble receptors. FEBS Lett 579 (2005) 5507-5511
38. Belnap D.M., McDermott Jr. B.M., Filman D.J., Cheng N., Trus B.L., Zuccola H.J., Racaniello V.R., Hogle J.M., and Steven A.C. Three-dimensional structure of poliovirus receptor bound to poliovirus. Proc Natl Acad Sci U S A 97 (2000) 73-78
39. Duque H., LaRocco M., Golde W.T., and Baxt B. Interactions of foot-and-mouth disease virus with soluble bovine alphaVbeta3 and alphaVbeta6 integrins. J Virol 78 (2004) 9773-9781
40. Hofmann H., Geier M., Marzi A., Krumbiegel M., Peipp M., Fey G.H., Gramberg T., and Pohlmann S. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem Biophys Res Commun 319 (2004) 1216-1221
41. Silberstein E., Xing L., van de Beek W., Lu J., Cheng H., and Kaplan G.G. Alteration of hepatitis A virus (HAV) particles by a soluble form of HAV cellular receptor 1 containing the immunoglobin-and mucin-like regions. J Virol 77 (2003) 8765-8774
42. Ullrich A., Coussens L., Hayflick J.S., Dull T.J., Gray A., Tam A.W., Lee J., Yarden Y., Libermann T.A., Schlessinger J., et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309 (1984) 418-425
43. Ware C.F. The TNF Superfamily-2008. Cytokine Growth Factor Rev 19 (2008) 183-186. An editorial preceding a special issue on the TNF superfamily including comprehensive tables of family members.
44. Peggs K.S., and Allison J.P. Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. Br J Haematol 130 (2005) 809-824
45. Aricescu A.R., and Jones E.Y. Immunoglobulin superfamily cell adhesion molecules: zippers and signals. Curr Opin Cell Biol 19 (2007) 543-550. A comprehensive overview of the IG family.
46. Levine S.J. Mechanisms of soluble cytokine receptor generation. J Immunol 173 (2004) 5343-5348. A systematic analysis of various mechanisms used to generate soluble receptors including 'Sheddase' metallo-proteanases.
47. Mantovani A., Bonecchi R., Martinez F.O., Galliera E., Perrier P., Allavena P., and Locati M. Tuning of innate immunity and polarized responses by decoy receptors. Int Arch Allergy Immunol 132 (2003) 109-115. A landmark review describing the general concept of natural decoy receptors as a means to regulate and fine tune cytokine activity.
48. Dinarello C.A. The interleukin-1 family: 10 years of discovery. FASEB J 8 (1994) 1314-1325
49. Colotta F., Re F., Muzio M., Bertini R., Polentarutti N., Sironi M., Giri J.G., Dower S.K., Sims J.E., and Mantovani A. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 261 (1993) 472-475
50. Dominitzki S., Fantini M.C., Neufert C., Nikolaev A., Galle P.R., Scheller J., Monteleone G., Rose-John S., Neurath M.F., and Becker C. Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol 179 (2007) 2041-2045. Trans-signaling provides a means to enhance the effect of a decoy rather than suppress the signal as illustrated for the case of soluble IL-6.
51. Mantovani A., Bonecchi R., and Locati M. Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat Rev Immunol 6 (2006) 907-918. Incorporation of Chemokine decoys into the equation of mechanisms for effective regulation of immune response. A comprehensive review bolstered with informative tables and charts.
52. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308
53. Pitti R.M., Marsters S.A., Lawrence D.A., Roy M., Kischkel F.C., Dowd P., Huang A., Donahue C.J., Sherwood S.W., Baldwin D.T., et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396 (1998) 699-703
54. McFadden G., and Murphy P.M. Host-related immunomodulators encoded by poxviruses and herpesviruses. Curr Opin Microbiol 3 (2000) 371-378
55. Alcami A., and Koszinowski U.H. Viral mechanisms of immune evasion. Mol Med Today 6 (2000) 365-372
56. Alcami A. Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol 3 (2003) 36-50
57. Sodhi A., Montaner S., and Gutkind J.S. Viral hijacking of G-protein-coupled-receptor signalling networks. Nat Rev Mol Cell Biol 5 (2004) 998-1012
58. Johnston J.B., and McFadden G. Poxvirus immunomodulatory strategies: current perspectives. J Virol 77 (2003) 6093-6100
59. Sakala I.G., Chaudhri G., Buller R.M., Nuara A.A., Bai H., Chen N., and Karupiah G. Poxvirus-encoded gamma interferon binding protein dampens the host immune response to infection. J Virol 81 (2007) 3346-3353. The interplay between Pox viruses and INFγ. Whereas the cytokine 'viroceptor' is not required for the replication of the virus, it does effect its virulence. The authors propose that modification of viruses by deletion of their viroceptors may provide for safer vaccines.
60. Nuara A.A., Walter L.J., Logsdon N.J., Yoon S.I., Jones B.C., Schriewer J.M., Buller R.M., and Walter M.R. Structure and mechanism of IFN-gamma antagonism by an orthopoxvirus IFN-gamma-binding protein. Proc Natl Acad Sci U S A 105 (2008) 1861-1866
61. Alejo A., Ruiz-Arguello M.B., Ho Y., Smith V.P., Saraiva M., and Alcami A. A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. Proc Natl Acad Sci U S A 103 (2006) 5995-6000
62. Vischer H.F., Leurs R., and Smit M.J. HCMV-encoded G-protein-coupled receptors as constitutively active modulators of cellular signaling networks. Trends Pharmacol Sci 27 (2006) 56-63. A critical analysis of the chemokine decoys produced in HCMV thus illustrating this mode of virus decoy action for Herpes viruses.
63. Lalani A.S., Barrett J.W., and McFadden G. Modulating chemokines: more lessons from viruses. Immunol Today 21 (2000) 100-106
64. Dagna L., and Lusso P. Virus-encoded chemokines, chemokine receptors and chemokine-binding proteins: new paradigms for future therapy. Future Virol 2 (2007) 353-368. An insightful analysis of the potential for novel anti-viral therapies based on viroceptors.
65. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., and Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117 (2008) 244-279
66. Goldenberg M.M. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther 21 (1999) 75-87 discussion 71-72
67. Gladman D.D. Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis. Nat Clin Pract Rheumatol 4 10 (2008) 510-511. A careful comparative analysis of anti-TNF drugs in patients suffering from psoriatic arthritis. Enanercept as compared to the two mAb-based drugs was found equally effective and thus it is concluded that patients should be allowed to choose the therapy best suited to them.
68. Lin W.W., and Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117 (2007) 1175-1183. An excellent review linking inflammation to the development of malignant disease.
69. Popivanova B.K., Kitamura K., Wu Y., Kondo T., Kagaya T., Kaneko S., Oshima M., Fujii C., and Mukaida N. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118 (2008) 560-570. Using a mouse model for inflammatory bowel disease and progression to colon cancer the authors illustrate the effect of Etanercept. This not only demonstrates the involvement of TNF in the progression to colon cancer but also the potency of its decoy in treatment.
70. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
71. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175 (1972) 409-416
72. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 6 (2007) 273-286. An extremely comprehensive and insightful review on the role of angiogenesis in cancer and its treatment. The article not only reviews the field in detail, it is exceptionally well illustrated and provides Prof Folkman's personal perspectives only months before his untimely death (January 2008).
73. Roskoski Jr. R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 62 (2007) 179-213. A comprehensive review of a central component in the biology of tumour progression.
74. Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99 (2002) 11393-11398
75. Aflibercept: VEGF Trap. Drugs R D 9 (2008) 261-269. A useful survey of the latest developments and clinical trials related to VEGF-trap
76. Riely G.J., and Miller V.A. Vascular endothelial growth factor trap in non small cell lung cancer. Clin Cancer Res 13 (2007) s4623-s4627
77. Verheul H.M., Hammers H., van Erp K., Wei Y., Sanni T., Salumbides B., Qian D.Z., Yancopoulos G.D., and Pili R. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 13 (2007) 4201-4208
78. Hoffman H.M., Throne M.L., Amar N.J., Sebai M., Kivitz A.J., Kavanaugh A., Weinstein S.P., Belomestnov P., Yancopoulos G.D., Stahl N., et al. Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58 (2008) 2443-2452
79. Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., Saldate C., Li T., Aranda R., Becker J.C., et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67 (2008) 1096-1103